Genesis Biotechnology Group

What Genesis Biotechnology Group does

Genesis Biotechnology Group (GBG) is a privately-held, vertically integrated biotechnology consortium headquartered in Hamilton, New Jersey, operating since at least 1997 through its core subsidiary Medical Diagnostic Laboratories (MDL). The group operates two principal segments: Genesis Clinical Diagnostics (encompassing MDL, SunPath-MDL, Institute for Biomarker Research, and 4path for anatomic pathology) which provides CLIA-certified, CAP-accredited molecular diagnostic testing using proprietary specimen collection platforms (OneSwab, UroSwab, NasoSwab) to clinicians across multiple specialties; and Genesis Drug Discovery & Development (GD3), a full-service preclinical contract research organization offering discovery biology, medicinal chemistry, DMPK, in vivo pharmacology leveraging over 150 patient-derived xenograft (PDX) models, and GLP/non-GLP toxicology and safety pharmacology in an AAALAC-accredited, FDA/USDA/OLAW-registered facility. As of the most recent reporting, GBG comprises approximately 15 wholly-owned subsidiaries serving thousands of clinicians across the United States and select international markets, plus pharmaceutical and biotechnology companies requiring preclinical CRO support.

The business model is enterprise B2B services-based: clinical diagnostic revenue is generated through laboratory testing fees billed to healthcare providers under fee-for-service arrangements with reimbursement via third-party payors, while CRO revenue is earned through project-based contracts with pharma/biotech sponsors. GBG holds a 60+ patent intellectual property estate covering proprietary diagnostic methods, biomarkers (e.g., DEK for bladder cancer, CIP2A for cervical cancer, PME-1 for endometrial cancer), and infectious disease detection technologies. Distribution occurs exclusively through direct enterprise relationships, with no public pricing transparency. Go-to-market emphasizes industry conference participation (AACR, ARVO, ASM-Microbe, Society of Toxicology) and academic partnerships (Yale University, Mercer County Community College).

Growth has been achieved primarily through an aggressive multi-year acquisition strategy rather than external equity funding, building out the CRO and diagnostics portfolio with additions including Comparative Biosciences (GLP toxicology), STATKING Clinical Services, BioBlocks and Organochem (preclinical chemistry), PharmOptima and NexusPharma (preclinical CRO), Integrated Analytical Solutions (PK profiling), JSS Medical Research (clinical services), and the 2021 entry into women's health clinical services via the Montclair Breast Center acquisition. The company remains founder-controlled under CEO Eli Mordechai, has not raised disclosed external funding rounds, and has no public listing.

Name

Genesis Biotechnology Group

Legal name

Genesis Biotechnology Group, LLC

Website

https://genesisbiotechgroup.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Genesis Biotechnology Group is a privately-held, vertically integrated biotechnology consortium operating CLIA-certified molecular diagnostic laboratories (MDL, SunPath-MDL, IBR, 4path) and a full-service preclinical CRO (GD3), serving clinicians across multiple specialties and pharmaceutical/biotech companies across the United States and select international markets.

Ownership category

akta.pro rank

Product category

Clinical Laboratory and Contract Research Services

NAICS

Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

Keywords

• Molecular diagnostic testing
• Preclinical drug discovery
• Contract research services
• Biomarker research services
• Clinical laboratory diagnostics

Headquarters

HQ city

Robbinsville

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Clinical Diagnostic Testing Services: Molecular diagnostic testing services provided through MDL and SunPath-MDL labs, offering PCR-based tests for viral, fungal, and bacterial infections. Services include Women's Health Molecular Biology, Immunology, Virology, Microbiology, Mycology, Pharmacogenomics, Antimicrobial Resistance, and Oncology testing.
2. Contract Research Organization (CRO) Services: Full-service preclinical drug discovery and development services through Genesis Drug Discovery & Development (GD3), covering discovery biology, synthetic organic and medicinal chemistry, DMPK, in vivo pharmacology, disease models, and toxicology.
3. Biomarker Research Services: Multi-variant-based personal diagnostics and biomarker testing services through the Institute for Biomarker Research (IBR), utilizing next-generation DNA sequencing for disease evaluation and patient stratification.
4. Anatomic Pathology Services: CAP-accredited anatomic pathology services provided by 4path, Ltd. serving clients in the Great Lakes Region with expertise in multiple specialties including Podiatry, Gastroenterology, Urology, Dermatology, Breast, Gynecology, and Orthopedics.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Genesis Biotechnology Group is a vertically integrated consortium operating CLIA-certified, CAP-accredited molecular diagnostic laboratories (Medical Diagnostic Laboratories, SunPath-MDL, Institute for Biomarker Research, 4path) and a full-service preclinical contract research organization (Genesis Drug Discovery & Development). The company delivers high-complexity automated molecular analysis, PCR-based testing, next-generation DNA sequencing, proprietary specimen collection platforms (OneSwab, UroSwab, NasoSwab), and GLP/non-GLP toxicology services to clinicians, pharmaceutical firms, and biotech companies.

Product overview

Genesis Biotechnology Group operates as a consortium of vertically integrated companies organized into two primary divisions: Genesis Drug Discovery and Genesis Clinical Diagnostics. Genesis Drug Discovery & Development (GD3) is a full-service contract research organization offering preclinical drug discovery services including discovery biology, synthetic chemistry, DMPK, in vivo pharmacology with over 150 PDX models, and GLP/non-GLP toxicology. Genesis Clinical Diagnostics encompasses Medical Diagnostic Laboratories (MDL) and SunPath-MDL (CLIA certified CAP accredited reference laboratories performing molecular diagnostics using proprietary OneSwab, UroSwab, and NasoSwab platforms), the Institute for Biomarker Research (next generation DNA sequencing for biomarker discovery), and 4path (anatomic pathology services). The company also acquired Montclair Breast Center in 2021 as part of its women's health expansion. The portfolio spans drug discovery research services, clinical laboratory diagnostics, and women's health services, united by the goal of improving patient care through drug discovery and personalized clinical diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

• Genesis Drug Discovery & Development (GD3): Fully integrated, full-service contract research organization (CRO) focused on providing services to support preclinical drug discovery and development
• Genesis Clinical Diagnostics
• OneSwab
• UroSwab
• NasoSwab

Products and services

• Medical Diagnostic Laboratories (MDL) A CLIA-certified CAP-accredited reference laboratory performing high-complexity, automated DNA-based molecular analysis using proprietary specimen collection platforms (OneSwab, UroSwab, NasoSwab). Provides clinicians with diagnostic information for viral, fungal, and bacterial infections across Women's Health Molecular Biology, Immunology, Virology, Microbiology, Mycology, Pharmacogenomics, Antimicrobial Resistance, and Oncology.
• SunPath-MDL A CLIA-certified CAP-accredited reference laboratory offering highly specialized molecular diagnostic testing using PCR-based assays from single swab specimens, providing clinicians with diagnostic information for viral, fungal, and bacterial infections.
• Institute for Biomarker Research (IBR) Dedicated to innovation in multi-variant-based personal diagnostics for disease evaluation, progression, regression, and patient stratification. Uses next-generation DNA sequencing to create, validate, and commercialize diagnostic assays and enable enhanced screening of gene mutation carriers and family members.
• 4path, Ltd. A CAP-accredited anatomic pathology laboratory in the Chicagoland area providing pathology services across Podiatry, Gastroenterology, Urology, Dermatology, Breast, Gynecology, and Orthopedics specialties.
• Genesis Drug Discovery & Development (GD3) A fully integrated, full-service contract research organization (CRO) providing preclinical drug discovery and development services, including discovery biology, synthetic organic and medicinal chemistry, DMPK, in vivo pharmacology, disease modeling with over 150 unique PDX models, and GLP/non-GLP toxicology and safety pharmacology. Operates within an AAALAC-accredited facility registered with the FDA, USDA, and OLAW.
• Montclair Breast Center A New Jersey-based facility specializing in breast health diagnostics and treatment, acquired in 2021 as part of GBG's expansion into women's health and vision for building a women's health research center.
• OneSwab Specimen Collection Platform A proprietary specimen collection and transport platform developed by MDL that enables multiple molecular diagnostic tests to be performed from a single swab specimen, including tests for infectious diseases, women's health, and oncology.

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Yale UniversitycoreStrategic or Co-development Partner · 9 December 2020GBG announced a partnership with Yale University for CRO relationship services. The partnership was renewed for a second year in December 2020, indicating a significant academic collaboration for preclinical drug discovery research.
• Ophthy-DS, Inc.coreStrategic or Co-development Partner · 26 March 2019Genesis Drug Discovery & Development announced an operating agreement with Ophthy-DS, Inc., focusing on ophthalmic disorders drug development and research services.
• Mercer County Community CollegeminorStrategic or Co-development Partner · 1 December 2016Mercer County Community College launched a partnership with GBG to give students the opportunity to work while they learn, providing internship opportunities across various departments.
• TrustmarkminorOthersHealth insurance plan provider included in GBG's accepted health plans for employees
• CignaminorOthersHealth insurance plan provider included in GBG's accepted health plans for employees
• Kaiser PermanenteminorOthersHealth insurance plan provider for California employees included in GBG's accepted health plans

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Quest Diagnostics: One of the largest clinical laboratory services companies in the US, providing molecular diagnostics, women's health, and infectious disease testing that directly overlaps with MDL's and IBR's services; a comparable incumbent across GBG's diagnostics half though much larger.
• Labcorp Holdings (Laboratory Corporation of America): Major US clinical diagnostics provider with a molecular and esoteric testing menu overlapping MDL/SunPath-MDL/IBR's offerings; comparable as a broad incumbent in the same reference-laboratory category, though with substantially broader national reach.
• WuXi AppTec: Large global CRO/CDMO offering preclinical and clinical services that overlap with GD3's discovery biology, medicinal chemistry, DMPK, and in vivo pharmacology capabilities; a broadly comparable incumbent though much larger and geographically diversified.
• ICON plc: Global CRO providing preclinical through clinical research services; comparable to GD3's drug discovery capabilities and somewhat to its clinical-stage subsidiaries (JSS Medical Research, STATKING Clinical Services).
• Eurofins Scientific: International laboratory services group operating clinical diagnostics and pharma testing labs; comparable to MDL/SunPath-MDL/4path's clinical laboratory operations across multiple specialties with much broader geographic reach.

Direct peers

• Charles River Laboratories: Premier preclinical CRO offering discovery, safety assessment, and research models (including PDX); GD3's preclinical drug discovery and 150+ PDX models position it as a direct peer to Charles River's Research Models & Services segment.
• Myriad Genetics: Specialized molecular diagnostics company with focus on genetic testing for cancer and women's health, mirroring IBR's and MDL's next-gen sequencing and hereditary cancer test offerings; competes in overlapping oncogenomics and pharmacogenomics markets.
• NeoGenomics Laboratories: Specialized oncology-focused clinical laboratory providing molecular diagnostics, next-gen sequencing, and pathology services that directly overlap with IBR's biomarker research and MDL's oncology testing capabilities.
• Crown Bioscience: Preclinical CRO and oncology research services provider with large PDX model library for in vivo pharmacology — closely comparable to GD3's PDX-anchored oncology discovery and translational research offerings.
• BioReference Laboratories (OPKO Health): Specialized clinical reference laboratory offering molecular diagnostics, women's health, and oncology testing services directly comparable in menu scope and customer base to MDL/SunPath-MDL.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/genesisbiojobs
• LinkedInlinkedin.com/company/2853321

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genesis Biotechnology Group